SR PHARMA SAYS ATUGEN UNIT WILL RECEIVE ROYALTIES FROM LICENSING DEAL

Shares of British biotechnology company SR Pharma PLC surged Tuesday after the company said its Atugen AG subsidiary will receive payments of up to US$95 million (€74.3 million) as well as royalties as a result of entering into a licensing agreement with Pfizer Inc. and Quark Biotech Inc. International Herald Tribune (http://www.iht.com/articles/ap/2006/09/26/business/EU_FIN_Britain_Germany_SR_Pharma.php)